Home » Newsletters » BioWorld Science

BioWorld Science

April 4, 2013

View Archived Issues

Convergence reports encouraging interim data from phase II study in trigeminal neuralgia

Regenx Biosciences Consortium receives European Commission grant for rare disease

A nasal proteasome-based therapy shows promise in animal models of AD

SUH-1210 simultaneously targets alpha- and beta-secretase activity

pan-Bcr-Abl inhibitor to overcome mutation-acquired resistance to imatinib identified

Characterization and in vivo efficacy of novel voltage-gated calcium channel blocker RQ-00311651

Protalix BioTherapeutics treats first patient in phase I study of PRX-112

Dainippon Sumitomo gains rights to two Edison Pharmaceuticals compounds

Long-term results show sapropterin is safe and well tolerated in pediatric patients with PKU

NIH grant awarded to Actinobac Biomed for Leukothera development

Biomarin plans phase I/II study of BMN-190 in Batten disease

Toxicology data encourage clinical development of OMS-721

Hydrea approved for essential thrombocythemia and polycythemia vera in Japan

Wakamoto and DWTI sign license agreement for antiglaucoma agent

Elan closes Tysabri transaction

Daratumumab granted FDA fast track designation

Abbott's new test for testicular cancer and birth defects obtains FDA approval

Mitsubishi Pharma launches BindRin in Germany and Austria

Cytokinetics begins first-in-human phase I trial of CK-2127107

Dainippon Sumitomo Pharma's European subsidiary changes name

Sanofi patents novel K(2P)3.1 blockers

Theraclone Sciences reports topline data from phase I TCN-202 trial

Spanish group prepares novel prostanoid EP1 receptor antagonists

Imperial Innovations researchers describe anti-DDR1 antibodies

Chiesi Farmaceutici patent describes human neutrophil elastase inhibitors